G

Genexine Inc
KOSDAQ:095700

Watchlist Manager
Genexine Inc
KOSDAQ:095700
Watchlist
Price: 4 470 KRW -0.89% Market Closed
Market Cap: 203.6B KRW

Gross Margin
Genexine Inc

7%
Current
-16%
Average
62.8%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
7%
=
Gross Profit
302.3m
/
Revenue
4.3B

Gross Margin Across Competitors

No Stocks Found

Genexine Inc
Glance View

Market Cap
203.3B KRW
Industry
Biotechnology

Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.

Intrinsic Value
658.11 KRW
Overvaluation 85%
Intrinsic Value
Price
G
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
7%
=
Gross Profit
302.3m
/
Revenue
4.3B
What is the Gross Margin of Genexine Inc?

Based on Genexine Inc's most recent financial statements, the company has Gross Margin of 7%.

Back to Top